According to the latest report by IMARC Group, titled “Global Cancer Cachexia Market Size, Share, Industry Trends, Growth, Opportunity and Forecast 2022-2027“, the global cancer cachexia market reached a value of US$ 1.88 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 2.53 Billion by 2027, exhibiting a CAGR of 4.80% during 2022-2027.
Cancer cachexia refers to a multifactorial wasting syndrome characterized by weight loss, anemia, systematic inflammation, anorexia, asthenia, involuntary loss of lean body mass and appetite, and negative protein and energy balance. It is caused due to various chronic conditions, such as tuberculosis, chronic renal failure, multiple sclerosis, human immunodeficiency virus (HIV), and chronic obstructive pulmonary disease (COPD). Cancer cachexia can be treated using several therapeutics, including progestogen, corticosteroid, and combination therapy, to alleviate the symptoms, enhance the response to chemotherapy, improve the quality of patient life, and increase the survival rate.
Base Year: 2021
Forecast Year: 2022-2027
Cancer Cachexia Market Trends and Drivers:
The global cancer cachexia market is primarily driven by the rising incidences of cancer cachexia among cancer patients. In addition, patients and healthcare providers are shifting toward combinational therapies for improving lean body mass (LBM) through pharmacological and non-pharmacological treatment.
Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/cancer-cachexia-market/requestsample
Along with this, the growing adoption of several appetite stimulants, such as megestrol acetate, dexamethasone, and methylprednisolone, for enhancing digestion has catalyzed the product demand. Furthermore, the increasing public and private investments in research and development (R&D) activities to introduce advanced therapeutics and drugs for cancer cachexia treatment have positively influenced the market growth.
Other factors, including the growing awareness regarding the availability of novel therapeutic drugs for cancer cachexia, expanding geriatric population, favorable government initiatives, improving healthcare infrastructure, and technological advancements, are also anticipated to propel the market growth.
Note: We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.
Global Cancer Cachexia Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
AAVogen Inc., Actimed Therapeutics Ltd., Aphios Corporation, Artelo Biosciences Inc., AVEO Pharmaceuticals Inc., Fresenius Kabi AG (Fresenius SE & Co. KGaA), Helsinn Healthcare SA, Merck & Co. Inc., NGM Biopharmaceuticals Inc., Pfizer Inc. and Tetra Bio-Pharma.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/cancer-cachexia-market
The report has segmented the market on the basis of region, therapeutics, mode of action and distribution channel.
Breakup by Therapeutics:
Breakup by Mode of Action:
Weight Loss Stabilizers
Breakup by Distribution Channel:
Breakup by Region:
North America: (United States, Canada)
Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
Latin America: (Brazil, Mexico, Others)
Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
Market Performance (2016-2021)
Market Outlook (2022- 2027)
Porter’s Five Forces Analysis
Market Drivers and Success Factors
Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Other Reports :
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800